RXRX vs. CRSP
Compare and contrast key facts about Recursion Pharmaceuticals, Inc. (RXRX) and CRISPR Therapeutics AG (CRSP).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: RXRX or CRSP.
Key characteristics
| RXRX | CRSP | |
|---|---|---|
| YTD Return | -32.56% | -23.74% |
| 1Y Return | -22.40% | -5.61% |
| 3Y Return (Ann) | -37.32% | -26.01% |
| Sharpe Ratio | -0.27 | -0.12 |
| Daily Std Dev | 85.39% | 58.68% |
| Max Drawdown | -88.97% | -81.61% |
| Current Drawdown | -83.91% | -77.27% |
Fundamentals
| RXRX | CRSP | |
|---|---|---|
| Market Cap | $1.85B | $4.17B |
| EPS | -$1.66 | -$3.20 |
| Total Revenue (TTM) | $49.20M | $201.02M |
| Gross Profit (TTM) | -$12.82M | $48.82M |
| EBITDA (TTM) | -$360.41M | -$340.10M |
Correlation
The correlation between RXRX and CRSP is 0.57, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
Performance
RXRX vs. CRSP - Performance Comparison
In the year-to-date period, RXRX achieves a -32.56% return, which is significantly lower than CRSP's -23.74% return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
RXRX vs. CRSP - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Recursion Pharmaceuticals, Inc. (RXRX) and CRISPR Therapeutics AG (CRSP). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
RXRX vs. CRSP - Dividend Comparison
Neither RXRX nor CRSP has paid dividends to shareholders.
Drawdowns
RXRX vs. CRSP - Drawdown Comparison
The maximum RXRX drawdown since its inception was -88.97%, which is greater than CRSP's maximum drawdown of -81.61%. Use the drawdown chart below to compare losses from any high point for RXRX and CRSP. For additional features, visit the drawdowns tool.
Volatility
RXRX vs. CRSP - Volatility Comparison
Recursion Pharmaceuticals, Inc. (RXRX) has a higher volatility of 23.58% compared to CRISPR Therapeutics AG (CRSP) at 12.25%. This indicates that RXRX's price experiences larger fluctuations and is considered to be riskier than CRSP based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
RXRX vs. CRSP - Financials Comparison
This section allows you to compare key financial metrics between Recursion Pharmaceuticals, Inc. and CRISPR Therapeutics AG. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities